Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

9.1%

2 terminated/withdrawn out of 22 trials

Success Rate

88.2%

+1.7% vs industry average

Late-Stage Pipeline

68%

15 trials in Phase 3/4

Results Transparency

0%

0 of 15 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
9(45.0%)
Phase 3
6(30.0%)
Phase 1
3(15.0%)
Phase 2
2(10.0%)
20Total
Phase 4(9)
Phase 3(6)
Phase 1(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials
NCT06183216Phase 1Completed

A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

Role: lead

NCT05381350Phase 3Completed

Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above

Role: lead

NCT05112913Phase 4Unknown

Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 Years

Role: lead

NCT04992260Phase 3Completed

Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents

Role: lead

NCT05137418Phase 3Completed

Safety and Immunogenicity of COVID-19 Vaccine, Inactivated in Healthy Population Aged From 3 to 11 Years

Role: lead

NCT04993365Phase 4Completed

Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)

Role: lead

NCT04551547Phase 1Completed

Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19

Role: lead

NCT04911790Phase 4Completed

Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults

Role: lead

NCT05198336Phase 4Completed

Immunogenicity of an Inactivated COVID-19 Vaccine

Role: lead

NCT05254236Phase 2Withdrawn

Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated Vaccine in Healthy Adults in in Hong Kong

Role: lead

NCT05156632Phase 3Withdrawn

Efficacy,Immunogenicity and Safety of COVID-19 Vaccine , Inactivated Booster Dose in Adults Aged 18 Years and Above

Role: lead

NCT05367895Unknown

Effectiveness of Inactivated COVID-19 Vaccine of the First Booster Dose

Role: lead

NCT04974164Completed

Effectiveness of COVID-19 Vaccine for Prevention of COVID-19 in the Dominican Republic

Role: lead

NCT05150496Phase 2Suspended

Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in Turkey

Role: lead

NCT05165732Phase 4Suspended

Safety and Immunogenicity Study of Booster Vaccination With COVID-19 Vaccine (Vero Cell),Inactivated From Different Manufactures for Prevention of COVID-19

Role: lead

NCT04953325Phase 4Completed

Immunogenicity and Safety of an Inactivated COVID-19 Vaccine

Role: lead

NCT04894227Phase 4Completed

Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults

Role: lead

NCT04352608Phase 1Completed

Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)

Role: lead

NCT05065177Phase 3Completed

Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants

Role: lead

NCT04962308Phase 4Unknown

Clinical Trial of Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults

Role: lead